Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remodulin for Post-Fontan Pulmonary Hypertension
NCT02865733Phase 3Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, single-blind trial of treprostinil in pulmonary hypertension (PH) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Composite variable of death, failing Fontan or failed Fontan at 48 hours. Started Aug 2016; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02865733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02865733.